Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
30 October, 2020 11:23 IST
Aurobindo Pharma receives EIR for Hyderabad unit
Source: IRIS | 19 Feb, 2020, 05.39PM
Rating: NAN / 5 stars.
Comments  |  Post Comment

Aurobindo Pharma, a mid-size pharmaceutical company, notified the stock exchanges that it had received an establishment inspection report (EIR) from the US drug regulator (USFDA) for Hyderabad unit.

It said ''the company has received EIR with voluntary action initiated (VAI) status from the United States Food and Drug Administration (USFDA).''

In November, USFDA inspected Unit IV, a general injectable formulation manufacturing facility at Pashamylaram in Hyderabad and had issued 'Form 483' with 14 observations.

Shares of the company gained Rs 102.05, or 20.4%, to settle at Rs 602.25. The total volume of shares traded was 897,415 at the BSE (Wednesday).

 Post Comment
Name Email
Security Code type    into this box
Related Articles
Persistent Systems - 29-Oct-2020 21:46
Persistent Systems - 29-Oct-2020 21:46
Titan Company quarterly earnings fall 37.81% - 29-Oct-2020 14:27
Titan Company quarterly net declines 37.81% - 29-Oct-2020 14:24
Titan Company quarterly profit drops 37.81% - 29-Oct-2020 13:58
Sensex falls 225 points - 28-Oct-2020 14:11
sensex trades lower - 28-Oct-2020 13:08
sensex opens higher - 28-Oct-2020 12:20
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer